Basic cancer research
Final report: PCM Report – Basic research
Investigator: Bertha Brodin
The emerging sequencing technologies of the 21st century has allowed the mapping of cancer cell genomes, transcriptomes and proteomes, leading to a fine sub classification of tumor types and to the discovery of diagnostic, predictive and therapeutic targets. Further, molecular technologies for manipulation of gene expression in eukaryotic cells have contributed to the understanding of the biologic relevance of these biomarkers. With the addition of multiplexing image technologies for visualization of proteins in situ, the architecture of normal and malignant human tissue proteomes have been generated.
These types of analysis are gradually being adopted in routine diagnostics and the information generated is used for cancer group classification and to define individual genetic and phenotypic landscapes.
However, only few biomarker discoveries have been adopted successfully into the treatment of cancer patients and the translation from basic cancer research to patient treatment is still lengthy and challenging.
Objectives and delivery
The aim of the present investigation is to make a survey among basic research groups to define their level of commitment in personalised cancer medicine (PCM) research and to identify the possible hinders towards clinical results.
Through interviews, we will gather the researchers conceptual insights into PCM and their needs for multidisciplinary networks.
This information will be summarized in a report that will help to generate interventions that may accelerate the implementation of basic research findings into clinical practice.